Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Maria T Papadopoulou, Paraskevi Panagopoulou, Efstathia Paramera, Alexandros Pechlivanis, Christina Virgiliou, Eugenia Papakonstantinou, Maria Palabougiouki, Maria Ioannidou, Eleni Vasileiou, Athanasios Tragiannidis, Evangelos Papakonstantinou, Georgios Theodoridis, Emmanuel Hatzipantelis, Athanasios Evangeliou
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy. Despite high cure rates, several questions remain regarding predisposition, response to treatment, and prognosis of the disease. The role of intermediary metabolism in the individualized mechanistic pathways of the disease is unclear. We have hypothesized that children with any (sub)type of ALL have a distinct metabolomic fingerprint at diagnosis when compared: (i) to a control group; (ii) to children with a different (sub)type of ALL; (iii) to the end of the induction treatment...
March 24, 2024: Diagnostics
#2
JOURNAL ARTICLE
Sally K Stauder, Shalmali R Borkar, Amy E Glasgow, Tage L Runkle, Mark E Sherman, Aaron C Spaulding, Michael M Mohseni, Christopher C DeStephano
OBJECTIVE: To determine associations of incident cancer diagnoses in women with recent emergency department (ED) care. PATIENTS AND METHODS: A retrospective cohort study analyzing biological females aged 18 years and older, who were diagnosed with an incident primary cancer (12 cancer types studied) from January 1, 2015, to December 31, 2021, from electronic health records. The primary outcome was a cancer diagnosis within 6 months of a preceding ED visit. Secondary outcomes included patient factors associated with a preceding ED visit...
June 2024: Mayo Clinic Proceedings. Innovations, Quality & Outcomes
#3
JOURNAL ARTICLE
Qie Guo, Jia-Lin Sun, Ran Li, Xiao Li
PURPOSE: It remains unclear whether the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T genetic variants are associated with methotrexate (MTX) elimination delay and high-dose MTX (HD-MTX) toxicities in the treatment of pediatric acute lymphoblastic leukemia (ALL). The aim of our study was to analyze the potential predictive role of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T in toxicities and the relationship between these variants and MTX elimination delay during HD-MTX therapy in pediatric ALL patients...
2024: International Journal of General Medicine
#4
JOURNAL ARTICLE
Irfan Al-Hussaini, Brandon White, Armon Varmeziar, Nidhi Mehra, Milagro Sanchez, Judy Lee, Nicholas P DeGroote, Tamara P Miller, Cassie S Mitchell
Background : Datasets on rare diseases, like pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), have small sample sizes that hinder machine learning (ML). The objective was to develop an interpretable ML framework to elucidate actionable insights from small tabular rare disease datasets. Methods : The comprehensive framework employed optimized data imputation and sampling, supervised and unsupervised learning, and literature-based discovery (LBD). The framework was deployed to assess treatment-related infection in pediatric AML and ALL...
March 20, 2024: Journal of Clinical Medicine
#5
JOURNAL ARTICLE
Klementina Črepinšek, Nika Klobučar, Tine Tesovnik, Robert Šket, Barbara Jenko Bizjan, Jernej Kovač, Marko Kavčič, Tomaž Prelog, Lidija Kitanovski, Janez Jazbec, Maruša Debeljak
In this study, we aimed to identify patients within our B-ALL cohort with altered PAX5 . Our objective was to use a comprehensive analysis approach to characterize the types of genetic changes, determine their origin (somatic/germline), and analyze the clinical outcomes associated with them. A consecutive cohort of 99 patients with B-ALL treated at the Children's Hospital of the UMC Ljubljana according to the ALL IC-BFM 2009 protocol was included in our study. We used RNA sequencing data for gene expression analysis, fusion gene detection and single nucleotide variant identification, multiplex-ligation dependent probe amplification for copy number variation assessment, and Sanger sequencing for germline variant detection...
March 15, 2024: Cancers
#6
JOURNAL ARTICLE
Stien De Coninck, Juliette Roels, Beatrice Lintermans, Sara T'Sas, Tom Taghon, David J Curtis, Tim Pieters, Steven Goossens, Pieter Van Vlierberghe
TET2-mediated DNA demethylation plays a pivotal role in regulating pre-leukemic clonal expansion in acute myeloid leukemia (AML), where TET2 mutations are also linked to AML progression. However, its function in other types of leukemias, including T-cell acute lymphoblastic leukemia (T-ALL), remains unclear. Here, we used two different T-ALL mouse models to study the possible tumor suppressor role of Tet2 in pre-leukemic T-ALL. Overexpression of Tet2 resulted in a mild but significant increase in T-ALL latency in the immature CD2-Lmo2tg T-ALL mouse model, but no effect on survival was observed in the mature Lck-Cretg/+ Ptenfl/lf T-ALL mouse model...
March 27, 2024: Blood Advances
#7
JOURNAL ARTICLE
Adán Germán Gallardo Rodríguez, Irma Olarte Carrillo, Adolfo Martínez Tovar, Rafael Cerón Maldonado, Emmanuel Martínez Moreno, Christian Omar Ramos Peñafiel
IL-15 is a proinflammatory myokine essential for activating NK cells and CD8+ T lymphocytes, and its overexpression has been related to reducing overall survivorship in patients with acute lymphoblastic leukemia (ALL). Physical exercise has been shown to be safe, feasible, and beneficial in hematological cancers. Exercise requires the activation of muscles that secrete cytokines, such as IL-15, causing immune mobilization. The objective was to compare the outcomes of two training routines on IL-15 and survival prognosis in adult patients diagnosed with ALL...
December 21, 2023: Journal of Functional Morphology and Kinesiology
#8
JOURNAL ARTICLE
Danyang Li, Yigang Yuan, Chen Meng, Zihan Lin, Min Zhao, Liuzhi Shi, Min Li, Daijiao Ye, Yue Cai, Xiaofei He, Haige Ye, Shujuan Zhou, Haixia Zhou, Shenmeng Gao
BACKGROUND: miR-182 promoter hypermethylation frequently occurs in various tumors, including acute myeloid leukemia, and leads to low expression of miR-182. However, whether adult acute lymphocyte leukemia (ALL) cells have high miR-182 promoter methylation has not been determined. METHODS: To assess the methylation status of the miR-182 promoter, methylation and unmethylation-specific PCR analysis, bisulfite-sequencing analysis, and MethylTarget™ assays were performed to measure the frequency of methylation at the miR-182 promoter...
March 26, 2024: Clinical Epigenetics
#9
JOURNAL ARTICLE
Bradley Roth, Muhammed A Moukhtar Hammad, Daniel I Sanford, Molly Piper, David W Barham, Faysal A Yafi, Lawrence C Jenkins
INTRODUCTION: The associated symptoms of hypogonadism have been reported in patients with various types of cancer. However, the prevalence and significance of hypogonadism among certain hematologic malignancies have not been completely summarized in recent literature. OBJECTIVE: In this review we aimed to examine the current literature on hypogonadism in patients with hematologic malignancies, with emphasis on leukemias, lymphomas, and multiple myeloma (MM). METHODS: This review included relevant studies published before July 2023 that were retrieved through a search of PubMed using the keywords "hematologic cancer," "hematologic malignancy," blood cancer," "leukemia," "lymphoma," "hypogonadism," "multiple myeloma," and "testosterone...
March 21, 2024: Sexual Medicine Reviews
#10
Yue Yin, Kaini Shen, Hanyu Li, Lu Zhang
Introduction With the increasing use of Blinatumomab in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), including MRD-positive cases, awareness of its adverse effects has gradually improved. Pneumocystis jiroveci pneumonia (PCP) associated with Blinatumomab therapy is rare. Case Presentation We present a case of PCP in a patient undergoing Blinatumomab therapy. A 70-year-old female diagnosed with Philadelphia-like, CRLF2 overexpression B-cell precursor ALL received Blinatumomab as consolidation therapy after achieving complete remission with prior induction chemotherapy...
March 20, 2024: Chemotherapy
#11
JOURNAL ARTICLE
Muhammad Awais, Md Nazmul Abdal, Tallha Akram, Areej Alasiry, Mehrez Marzougui, Anum Masood
In the field of medicine, decision support systems play a crucial role by harnessing cutting-edge technology and data analysis to assist doctors in disease diagnosis and treatment. Leukemia is a malignancy that emerges from the uncontrolled growth of immature white blood cells within the human body. An accurate and prompt diagnosis of leukemia is desired due to its swift progression to distant parts of the body. Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia that affects both children and adults...
2024: Frontiers in Oncology
#12
JOURNAL ARTICLE
Noha H Sayed, Mahmoud Hammad, Safeya A Abdelrahman, Hanan M Abdelgawad
Acute lymphoblastic leukemia (ALL) is the most prevailing cancer among children. Despite extensive studies, ALL etiology is still an unsolved puzzle. Long non-coding RNAs (lncRNAs) emerged as key mediators in cancer etiology. Several lncRNAs are dysregulated in ALL, leading to oncogenic or tumor-suppressive activities. Additionally, a relation between ABO blood groups and hematological malignancies was proposed. The current study intended to explore the association of lncRNAs, ANRIL and LINC-PINT, and their downstream targets, CDKN2A and heme oxygenase-1 (HMOX1), with the incidence of ALL and treatment response, and to determine the distribution of blood groups across different childhood ALL phenotypes...
June 2024: Non-Coding RNA Research
#13
JOURNAL ARTICLE
Kathryn P Goggin, Lu Lu, Danielle E Lee, Carrie R Howell, Deokumar Srivastava, Tara M Brinkman, Gregory T Armstrong, Nickhill Bhakta, Leslie L Robison, Mathew J Ehrhardt, Melissa M Hudson, Kevin R Krull, Ching-Hon Pui, Jeffrey Rubnitz, Kirsten K Ness, Joshua Wolf
IMPORTANCE: Children undergoing treatment for leukemia are at increased risk of severe sepsis, a dysregulated immune response to infection leading to acute organ dysfunction. As cancer survivors, they face a high burden of long-term adverse effects. The association between sepsis during anticancer therapy and long-term organ dysfunction in adult survivors of childhood cancer has not been examined. OBJECTIVE: To determine whether severe sepsis during therapy for leukemia in childhood is associated with subsequent chronic health conditions in adult survivors...
March 4, 2024: JAMA Network Open
#14
JOURNAL ARTICLE
Tonia Chinyelu Onyeka, Ifeoma Emodi, Alhassan Datti Mohammed, Akinyemi Olugbenga Ofakunrin, Adewumi Alabi, Justus Uchenna Onu, Nneka Iloanusi, Jude Ohaeri, Agnes Anarado, Musa Usman Umar, Gbenro Olukiran, Anthonia Sowunmi, Adeseye Akinsete, Bolanle Adegboyega, Ijeoma Nkemdilim Chibuzo, Olamijulo Fatiregun, Shehu Umar Abdullah, Mahmoud Jahun Gambo, Mohammad Aminu Mohammad, Fawaz Babandi, Mary Bok, Joyce Asufi, Patience Kanhu Ungut, Maryam Shehu, Saleh Abdullahi, Matthew Allsop, Iornum Shambe, Innocent Ugwu, Samuel Ikenga, Joyce Balagadde Kambugu, Eve Namisango
OBJECTIVES: High levels of caregiver burden (CB) are experienced by informal caregivers of pediatric patients with cancer. There is increasing evidence highlighting the extent of CB across sub-Saharan African countries, although there remains lack of interventions that target improvements in their experience. This study aimed to determine the impact of a structured psychoeducation program on caregivers' outcomes relating to preparedness to provide care, burden of caregiving, and quality of life (QoL)...
March 14, 2024: Palliative & Supportive Care
#15
JOURNAL ARTICLE
Hsi-Che Liu, Ying-Jung Huang, Tang-Her Jaing, Kang-Hsi Wu, Shih-Hsiang Chen, Shih-Chung Wang, Ting-Chi Yeh, Chih-Cheng Hsiao, Te-Kau Chang, Hsiu-Ju Yen, Fang-Liang Huang, Pei-Chin Lin, Jen-Yin Hou, Jiunn-Ming Sheen, Yu-Mei Liao, Tsung-Yen Chang, Yu-Chieh Chen, Shyh-Shin Chiou, Chao-Ping Yang, Ching-Hon Pui, Der-Cherng Liang, Lee-Yung Shih
This study investigates the potential utility of IKZF1 deletion as an additional high-risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD-guided TPOG-ALL-2013 protocol using 412 newly diagnosed B-ALL patients aged 1-18. IKZF1 status was determined using multiplex ligation-dependent probe amplification. IKZF1 deletions, when co-occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus ...
March 13, 2024: British Journal of Haematology
#16
REVIEW
Cheng-Hsien Wu, Te-Fu Weng, Ju-Pi Li, Kang-Hsi Wu
This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia...
February 21, 2024: International Journal of Molecular Sciences
#17
REVIEW
Kamonporn Kotemul, Watchara Kasinrerk, Nuchjira Takheaw
Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is an aggressive hematologic malignancy. T-ALL patients who are treated with chemotherapeutic drugs frequently relapse and become drug resistant. Therefore, antibody-based therapy is promising for T-ALL treatment. To successfully develop an antibody-based therapy for T-ALL, antibodies that induce death in malignant T cells but not in nonmalignant T cells are required to avoid the induction of secondary T-cell immunodeficiency...
2024: Exploration of targeted anti-tumor therapy
#18
JOURNAL ARTICLE
Jiawang Ou, Shiyu Deng, Chenhao Ding, Zihong Cai, Junjie Chen, Zicong Huang, Xiuli Xu, Jia Li, Zhengwei Wu, Bingqing Tang, Ting Zhang, Zhixiang Wang, Ya Zhou, Li Xuan, Qifa Liu, Hongsheng Zhou
Epigenetic modifier (EM) genes play important roles in the occurrence and progression of acute lymphoblastic leukemia (ALL). However, the prognostic significance of EM mutations in ALL has not yet been thoroughly investigated. This retrospective study included 205 adult patients with ALL engaged in a pediatric-type regimen. Based on targeted next-generation sequencing, they were divided into EM mutation group (EM-mut, n = 75) and EM wild-type group (EM-wt, n = 130). The EM-mut group showed a higher positive rate of minimal residual disease (MRD) on treatment day24 and before consolidation therapy (P = 0...
March 7, 2024: Annals of Hematology
#19
JOURNAL ARTICLE
Yanfei Luo, Ting Lin, Luhua Xian, Yue Zhao, Wenmin Li, Junru Liu, Mingwei Lan, Huizhuang Shan
OBJECTIVES: Central nervous system leukemia (CNSL) is one of the main causes of recurrence and death in patients with acute leukemia. This study aims to dynamically monitor minimal residual disease (MRD) in cerebrospinal fluid and bone marrow of patients with different types of acute leukemia by flow cytometry (FCM), and to compare the timeliness and consistency of MRD detection between the 2 methods to further explore the application value of monitoring MRD in cerebrospinal fluid. METHODS: A total of 199 patients with acute leukemia admitted to the Guangdong Provincial people's Hospital between October 2018 and January 2022 were retrospectively analyzed, and multiparametric FCM method was adopted to summarize and analyze MRD in cerebrospinal fluid of patients with different types of leukemia and MRD in cerebrospinal fluid and bone marrow specimens of the same patients, and its role in assessing the prognostic value of patients was discussed...
December 28, 2023: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
#20
JOURNAL ARTICLE
Janet Flores-Lujano, Aldo Allende-López, David Aldebarán Duarte-Rodríguez, Erika Alarcón-Ruiz, Lizbeth López-Carrillo, Teresa Shamah-Levy, Mariano E Cebrián, Ma Del Rocío Baños-Lara, Diana Casique-Aguirre, Jesús Elizarrarás-Rivas, Javier Antonio López-Aquino, Miguel Ángel Garrido-Hernández, Daniela Olvera-Caraza, Vanessa Terán-Cerqueda, Karina Beatriz Martínez-José, Pierre Mitchel Aristil-Chery, Enoch Alvarez-Rodríguez, Wilfrido Herrera-Olivares, Guillermo J Ruíz-Arguelles, Lénica Anahí Chavez-Aguilar, Aquilino Márquez-Toledo, Lena Sarahi Cano-Cuapio, Nuria Citlalli Luna-Silva, Maria Angélica Martínez-Martell, Anabel Beatriz Ramirez-Ramirez, Laura Elizabeth Merino-Pasaye, César Alejandro Galván-Díaz, Aurora Medina-Sanson, Maria de Lourdes Gutiérrez-Rivera, Jorge Alfonso Martín-Trejo, Emmanuel Rodriguez-Cedeño, Vilma Carolina Bekker-Méndez, María de Los Ángeles Romero-Tlalolini, Astin Cruz-Maza, Gerardo Juárez-Avendaño, Sonia Mayra Pérez-Tapia, Juan Carlos Rodríguez-Espinosa, Miriam Carmina Suárez-Aguirre, Fernando Herrera-Quezada, Anahí Hernández-Díaz, Lizbeth Alondra Galván-González, Minerva Mata-Rocha, Amanda Idaric Olivares-Sosa, Haydeé Rosas-Vargas, Silvia Jiménez-Morales, Mariana Cárdenas-González, María Elena Álvarez-Buylla Roces, Célida Duque-Molina, Rosana Pelayo, Juan Manuel Mejía-Aranguré, Juan Carlos Núñez-Enriquez
INTRODUCTION: Acute leukemias (AL) are the main types of cancer in children worldwide. In Mexico, they represent one of the main causes of death in children under 20 years of age. Most of the studies on the incidence of AL in Mexico have been developed in the urban context of Greater Mexico City and no previous studies have been conducted in the central-south of the country through a population-based study. The aim of the present work was to identify the general and specific incidence rates of pediatric AL in three states of the south-central region of Mexico considered as some of the marginalized populations of Mexico (Puebla, Tlaxcala, and Oaxaca)...
2024: Frontiers in Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
